Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation-Reference-Cited by-同舟云学术

Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation

Published:2022-09 Issue: Volume:Volume 16 Page:3421-3429
ISSN:1177-8881
Container-title:Drug Design, Development and Therapy
language:en
Short-container-title:DDDT

Author:

Yin Liang,Liu Kai-Cai^ORCID,Lv Wei-Fu,Xu Shao-Bao,Lu Dong,Zhou Chun-Ze,Cheng De-Lei^ORCID,Gao Zong-Gen,Shi Chang-Sheng,Su Ming-Xue

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology

Reference26 articles.

1. Hepatocellular carcinoma

2. Medical administration of the State Health Commission of the people’s Republic of China. Standard for diagnosis and treatment of primary liver cancer (2019 Edition). Elect J Compr Tumor Ther. 2020;6(02):55–85. Chinese.

3. Korean Liver Cancer Association; National Cancer Center. 2018 Korean liver cancer association-national cancer center Korea practice guidelines for the management of hepatocellular carcinoma. Gut Liver. 2019;13:227–299. doi:10.5009/gnl19024

4. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Camrelizumab Combined with Transcatheter Arterial Chemoembolization for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis;Clinics and Research in Hepatology and Gastroenterology;2024-09

2. A multicenter, real‐world study on effectiveness and safety of first‐line modified PD‐1 inhibitors with chemotherapy in advanced non‐small cell lung cancer (aNSCLC) with drive gene‐negative;Cancer Medicine;2024-02